References
- Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J
Med. 2003;349:583-596.
- Mankad AK, Seray I, Shah KB. Light-chain cardiac amyloidosis. Curr
Probl Cancer. 2017;41:144-56
- Maurer MS, Schwartz JH, Gundapaneni B, Elliot PM et al. Tafamidis
treatment for patient with transthyretinin amyloid cardiomyopathy. N
Engl J Med. 2018;379:1007-16
- Treibel TA, Fontana M, Gilbertson JA, Castelletti S, et al. Occult
transthyretin cardiac amyloidosis in severe calcific aortic stenosis.
Circ Cardiovasc Imaging. 2016;9(8):e005066.
- Xu B, Godoy RC, Rodriguez ER, Tan C, et al. Unrecognized cardiac
amyloidosis at the time of mitral valve surgery: incidence and
outcomes. Cardiology. 2019;1429(4):253-258
- Massoudy P, Szabo A, Dirsch O, Wienecke H, van de Wal H, Jakob H.
Amyloid of heart and lungs in a patient with low output syndrome after
coronary artery bypass grafting. Herz. 2003:28(5):453-6
- Fitzmaurice G, Wishart V, Graham A. An unexpected mortality following
cardiac surgery: A post-mortem diagnosis of cardiac amyloidosis. Gen
Thorac Cardiovasc Surg. 2013;61(7):417-21
- Zacek P, Medilek K, Lonsky V, Laco J. Cardiac amyloidosis in the
cardiosurgical operating room – a rare but fatal trap. Thorac
Cardiovasc surg. 2007;55(2):65-67
- Massias S, Vyssoulis G, Rizos I, Barbetseas I, Stefanadis C.
Progressive heart failure in a patient after coronary artery bypass
grafting. Hell J Cardiol. 2006;47:114-117